
BioMarin, founded in 1997, is a global biotechnology company that transforms lives through genetic discovery. The company focuses on developing targeted therapies that address the root causes of rare genetic diseases, bringing eight first-or best-in-class commercial treatments to market. Its pipeline features a portfolio of science-driven, patient-forward product candidates that expand treatment options across a broader spectrum of genetic disorders. BioMarin's distinctive approach combines rigorous research with a commitment to delivering innovative, life-changing therapies to patients worldwide.
The Executive Director, International Pricing, Access, Value, and Evidence will report to the SVP, Head of Pricing, Access, Value and Evidence (PAVE) and will be a member of PAVE leadership team, responsible for the strategic planning, design and local implementation of access and pricing strategies to support the launch, pricing and reimbursement of BioMarin's products in markets outside of the US in Europe, MEA, LaTam and APAC.
BioMarin, founded in 1997, is a global biotechnology company that transforms lives through genetic discovery. The company focuses on developing targeted therapies that address the root causes of rare genetic diseases, bringing eight first-or best-in-class commercial treatments to market. Its pipeline features a portfolio of science-driven, patient-forward product candidates that expand treatment options across a broader spectrum of genetic disorders. BioMarin's distinctive approach combines rigorous research with a commitment to delivering innovative, life-changing therapies to patients worldwide.